Clinical trial
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With…
NCT00175825 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00175825 |
|---|---|
| Title | A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. |
| Official title | A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug, Other |
| Interventions | Placebo, Brivaracetam |
| Enrollment | 210 |
| Start date | Nov 7, 2005 |
| Primary completion | Jun 29, 2006 |
| Completion | Jun 29, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Oct 2, 2018 |
| Countries | Brazil, India, Mexico, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: